Alluvi, previously BI 4744, offers a promising development in obesity therapy. This dual agonist targeting both GLP-1 and GIP receptors demonstrates impressive effectiveness in patient studies, arguably surpassing https://bookmarkfame.com/story21975126/alluvi-a-comprehensive-investigation-into-the-medication-s-prospects